The calculation of BCR::ABL1 decline rates (halving times) for our NR and R cohorts confirm the observations of Branford and others that the rate of BCR::ABL1 decline can serve as a prognostic discriminator of CML patients after the first 3 months of TKI treatment [10]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.